PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
申请人:Pfizer Inc.
公开号:US20040220186A1
公开(公告)日:2004-11-04
The invention provides compounds of Formula (I)
1
the stereoisomers and prodrugs thereof, and the pharmaceutically acceptable salts of the compounds, stereoisomers, and prodrugs, wherein A, P, J, x, and R
10
are as defined herein; pharmaceutical compositions thereof; and methods of using the pharmaceutical compositions for the treatment of diseases, including, diabetes, including type 1 and type 2 diabetes, hyperglycemia, dyslipidemia, impaired glucose tolerance, metabolic syndrome, and/or cardiovascular disease.